Tissue Regenix Group PLC Directorate Change (9693G)

TIDMTRX

RNS Number : 9693G

Tissue Regenix Group PLC

20 March 2020

Tissue Regenix Group plc

Directorate Change

Leeds, 20 March 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company"), the regenerative medical devices company, announces that John Samuel, Executive Chair, has informed the Board of his intention to step down from both that role and as a board member after 12 years with the Company.

The Board have appointed Jonathan Glenn, a current non-executive director of Tissue Regenix, to the position of non-executive Chair on an interim basis with immediate effect. Most recently Jonathan was CEO of Consort Medical from 2007 until its recent acquisition by Recipharm AB, and has strong operational experience in the sector. The Board will review the position of Chair in due course and further announcements will be made at the appropriate time.

Randeep Grewal, Chair of the Nomination Committee, commented: "On behalf of the Board I would like to thank John for his commitment and contribution to the Company over many years. John has been pivotal in building the Company from a small start-up to its present form.

I am pleased to welcome Jonathan Glenn to the position of interim Chair. Jonathan brings with him a deep understanding of the healthcare industry and experience in leading companies through successful growth phases. Jonathan's knowledge and leadership will be increasingly valuable as we look to secure the next stage of our commercial development."

For more Information:

 
 Tissue Regenix Group plc                        Tel: [phone] 
  Caitlin Pearson Head of Communications 
---------------------------------------------  -------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated      Tel: [phone] 
  Adviser and Broker) 
  Jonathan Senior / Alex Price / Ben Maddison 
---------------------------------------------  -------------------- 
 
 FTI Consulting                                 Tel: [phone] 
  Simon Conway / Victoria Foster Mitchell 
  / Mary Whittow 
=============================================  ==================== 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAPPUUGWUPUUQU

(END) Dow Jones Newswires

March 20, 2020 03:00 ET (07:00 GMT)